Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic SARS-CoV-2-specific T cells
- Development stage
- Unknown
- Lead developer
- QIMR Berghofer Medical Research Institute
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic SARS-CoV-2-specific T cells is an investigational, 'off-the-shelf' adoptive T-cell immunotherapy developed by the QIMR Berghofer Medical Research Institute. The therapy is composed of CD4+ and CD8+ memory T cells expanded from the blood of healthy convalescent donors who have previously recovered from COVID-19. These T cells are stimulated ex vivo with peptides spanning immunodominant SARS-CoV-2 antigens, specifically the spike (S), nucleocapsid (N), and membrane (M) proteins. The treatment is intended to provide rapid, pre-manufactured antiviral immunity to patients at high risk of severe COVID-19, such as immunocompromised individuals, by supplementing their immune system's ability to recognize and eliminate the virus.
- Other names
- allogeneic virus-specific T cellsSARS-CoV-2-specific T cellsSARS-CoV2-specific T cellsSARS-CoV 2-specific T cellsoff-the-shelf SARS-CoV-2-specific T cells
02
Targets
SARS-CoV-2 spike protein–derived peptides presented by HLA class I and IISARS-CoV-2 nucleocapsid protein-derived peptides presented by HLA class I and II
Beyond the preview
Go deeper on allogeneic SARS-CoV-2-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic SARS-CoV-2-specific T cells.